Status:
RECRUITING
The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Pancreatic Cancer.
Lead Sponsor:
Ruijin Hospital
Conditions:
Pancreatic Cancer
Eligibility:
All Genders
18-75 years
Brief Summary
This study aims to investigate the value of 68Ga-grazytracer in predicting the efficacy of immunotherapy for pancreatic cancer.
Detailed Description
The investigators will number all participants, create a medical record file, and record their basic information (gender, age) as well as contact information and medical history information. All parti...
Eligibility Criteria
Inclusion
- Pathological diagnosis of pancreatic cancer requiring combination immunotherapy after evaluation according to clinical guidelines
- Signed and dated informed consent form
- Commitment to comply with research procedures and co-operation in the implementation of the full research process 4 .aged 18-75 years old 5 .The patient is in good general condition with an expected survival of \> 6 months
Exclusion
- Patients with serious illnesses that researchers consider unsuitable for participation in this clinical study. Such as severe heart and lung failure, severe bone marrow suppression, severe liver and kidney dysfunction, etc.
- Intestinal perforation, complete intestinal obstruction
- Pregnant women and women who may be pregnant, women who are breastfeeding.
- Non-compliant person
Key Trial Info
Start Date :
September 24 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 31 2027
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06601010
Start Date
September 24 2024
End Date
August 31 2027
Last Update
December 11 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ruijin Hospital affiliated to Shanghai Jiao Tong University of Medicine
Shanghai, Shanghai Municipality, China, 200025